Celgene Corporation's Revlimid Improves Survival in Blood Cancer Patients
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in newly diagnosed blood cancer patients, potentially opening up the path for a wider use of the drug.
The company's shares were up 4 percent at $129.75 in premarket trade.
Help employers find you! Check out all the jobs and post your resume.
Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in newly diagnosed blood cancer patients, potentially opening up the path for a wider use of the drug.
The company's shares were up 4 percent at $129.75 in premarket trade.
Help employers find you! Check out all the jobs and post your resume.